BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

Noa DaganNoam BardaEldad KeptenOren MironShay PerchikMark A KatzMiguel A Hernán Marc LipsitchBen ReisRan D Balicer

Published in: The New England journal of medicine (2021)

This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19-related outcomes, a finding consistent with that of the randomized trial.

Keyphrases

coronavirus disease
sars cov
cross sectional
binding protein
respiratory syndrome coronavirus
metabolic syndrome
glycemic control